Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - November 4, 2002
Under the terms of the contract, two million units were shipped immediately. Two subsequent shipments of one million units each will follow over the next four months.
"Brazil's innovative national AIDS program has been a global leader, and we are delighted that FC plays such an important role in their prevention strategy," said Dr. Mary Ann Leeper, President of the Female Health Company.
"The Ministry of Health has created a model program. FC is part of a comprehensive prevention strategy that includes training, counseling, outreach, education and promotion for women and men to support and sustain behavior change," said Dr. Leeper.
The Ministry of Health has conducted numerous studies to ensure achievement of maximum public health impact. Since 1998, the Ministry of Health has ordered more than eight million female condoms. The program began with a very successful acceptability trial which included 100,000 units for distribution. The order expanded in 1999 to allow 13,000 Brazilians access to FC. During 2000 and 2001, the Ministry bought two million units each year.
This new four million unit order will allow the Ministry to have broader reach of its comprehensive prevention program.
"The Brazilian Ministry of Health is committed to ensuring access to all available prevention options. We know from our experience with FC that as we expand access to this option, more acts of sexual intercourse will be protected," said Denise Doneda, the head of Prevention in the Ministry's National AIDS Program.
During the recent XIV International AIDS Conference in Barcelona, Spain, in July 2002, several studies were presented.
In one Brazilian study to evaluate the acceptance and use of FC among HIV infected women, high rates of use (87%), acceptability (68%) and continuation (78%) of FC use were observed during the study with a reduction in the proportion of unprotected sexual acts from 14% to 6%. The study concluded that adding FC to contraceptive options with appropriate counseling was able to reduce unprotected sex among HIV infected women, a key target group of the program.
During the Conference, the Brazilian Ministry of Health emphasized that the introduction of FC has also helped empower women to negotiate safer sex with their partners and to become aware of their personal vulnerability to disease.
"The Brazil program is a wonderful example of the importance of developing a broad continuum to attack the HIV/AIDS pandemic, including prevention, care and treatment. These are not 'either/or' choices, we must ensure that comprehensive prevention programs go hand-in-hand with care, support and treatment initiatives," said Dr. Leeper. "We look forward to continued collaboration with the Government of Brazil and to working with them to replicate their experiences elsewhere."
In addition to the continued expansion of the Ministry's public sector FC program, the product is also available commercially through DKT do Brasil, FHC's Brazilian marketing partner. DKT do Brasil markets the product under the brand name Reality.
UNAIDS' supported studies show that when FC Female Condom is available as an option, there is a significant reduction in the incidence of sexually transmitted disease (STD) compared to when only the male condom is available.
Additional published research highlights that incorporating FC into prevention programs can be cost saving as it reduces the number of unprotected sexual acts, the incidence of STDs, and the costs related to treatment and care.
FC is the only product controlled by women that helps to prevent STDs, including HIV/AIDS and unintended pregnancy. It is made of polyurethane, which is strong and unlikely to rip or tear during use and unlikely to cause allergic reactions. It is manufactured in a state of the art facility in London, England.
The Female Health Company, based in Chicago, owns certain worldwide rights to FC Female Condom(TM), including product and technology patents in the United States, Japan, the United Kingdom, France, Italy, Germany, Spain, the European Patent Convention, Canada, The People's Republic of China, Brazil, South Korea and Australia.
"Safe Harbor" Statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of governmental regulations, both in the United States and abroad; the effects of competitive products and pricing pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company, dial toll-free via fax, 1-800-PRO-INFO and enter company code "FHCO." Also, visit FHC's Websites at http://www.femalehealth.com and http://www.femalecondom.org .
SOURCE The Female Health Company
Web Site: http://www.femalecondom.org http://www.femalehealth.com
021104
PR021107
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .